Navigation Links
Supreme Court to Decide Overtime Fate for Pharmaceutical "Sales Representatives" -- JacksonWhite, Kingsley & Kingsley and Sanford Wittels & Heisler
Date:4/11/2012

WASHINGTON, April 11, 2012 /PRNewswire/ -- On April 16, the U.S. Supreme Court will hear arguments in an important case under the Fair Labor Standards Act, Christopher v. SmithKline Beecham Corp. The specific question in the case is whether pharmaceutical sales representatives are eligible to receive overtime pay. The larger issue is the deference that is owed to the U.S. Department of Labor's interpretation of that statute.

The Fair Labor Standards Act and Department of Labor regulations require, in general, that employers pay 1.5 times an employee's regular hourly rate of pay for each hour worked in excess of 40 hours per week, unless the employee qualifies for an "exemption" from the overtime rules. One of those exemptions covers "outside salespersons," employees whose primary job duty is to sell products away from their employers' offices.

The Christopher case involves the overtime claims of pharmaceutical representatives who are employed by drug manufacturing giant GlaxoSmithKline, but who never received overtime pay despite working significantly more than 40 hours per week. The Glaxo reps visit doctors' offices on "detail calls," and promote Glaxo's products in the hope that doctors will prescribe and that patients will buy those products. 

The sticking point is that the reps don't sell any pharmaceuticals to the physicians they visit.  In fact, they are barred by federal law from doing so. So, while at a superficial glance, their work consists of some of the same activities as traditional salespeople, federal regulations actually prohibit them from selling their employer's drugs to doctors or anyone else. 

The Department of Labor has weighed in, strongly supporting the reps' position.

Glaxo, like other drug manufacturers, nonetheless maintains that its representatives are exempt from overtime pay based on the "outside salesperson" exemption. 

The Arizona law firm of JacksonWhite filed the lawsuit against Glaxo on behalf of plaintiffs Shane Christopher and Frank Buchanan. Shareholder Michael Pruitt argued the case before both the Federal District Court in Phoenix and a three-judge panel of the 9th U.S. Circuit Court of Appeals. At the same time, Jeremy Heisler and David Sanford of the law firm of Sanford Wittels and Heisler were shepherding a parallel lawsuit against Novartis. The conflict between the 2nd Circuit, which ruled for the reps, and 9th Circuit, which ruled for the drug companies, set the stage for the successful appeal of the 9th Circuit's decision to the Supreme Court. 

Now, numerous cases await the outcome of the April 16 argument. Since 2006, several similar cases have been filed against other pharmaceutical companies, including AstraZenica, Abbott Labs, Sanofi, and Pfizer. One of the firms involved in the Christopher case at the Supreme Court, Kingsley and Kingsley of Encino, California, is responsible for many of these cases. 

If the Supreme Court holds that the Glaxo representatives are not outside salespersons, all three firms anticipate that many more plaintiffs will contact them to become part of class or collective actions against multiple drug manufacturers to recover overtime pay. The amounts at stake are very substantial. For example, In re Novartis settled last month for 99 million dollars.

The case will be argued by Supreme Court advocate Thomas Goldstein of Goldstein and Russell, P.C., in Washington, D.C. Goldstein is one of the nation's preeminent Supreme Court attorneys; this will be his 25th argument before the Supreme Court. Goldstein teaches Supreme Court Litigation at both Stanford and Harvard Law Schools. After much preparation, the team is cautiously optimistic about the outcome of the appeal. "We believe that the Supreme Court will agree that the Department of Labor's view that a salesperson must actually 'sell' something is entirely sound," Goldstein said. 

The Supreme Court will likely issue a decision on the Christopher appeal in June 2012. 

Click here to read all briefs filed in the case.

To learn more, contact a member of the legal team at:
JacksonWhite:  www.pharmaovertime.com
40 N Center Street, Suite 200
Mesa, AZ 85201
888-866-2293

Kingsley & Kingsley:  www.pharmarepovertime.com
16133 Ventura Boulevard #1200
Encino, CA 91436
818-990-8300

Sanford Wittels & Heisler:  www.swhlegal.com
1350 Avenue of the Americas, Fl 31
New York, NY 10019
646-723-2947          

 


'/>"/>
SOURCE JacksonWhite
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
2. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
3. Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot
4. Supreme Court of Israel Rules in Favor of Sun Pharma
5. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
6. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
7. The Appellate Division of State Supreme Court has Upheld a Landmark 2010 Products Liability Verdict Which Found Cybex International Responsible for Catastrophic Injuries Suffered by a Cheektowaga Woman
8. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
9. Pharma CI Conference Amy Yueh Pays $52,000 to Apaporis LLC to Satisfy Judgment Against Her In Superior Court Of New Jersey Case
10. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
11. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... Tenn. and DALLAS , April 19, 2017 ... announced that the first patients in Nashville ... device in the Lower Esophageal Sphincter Stimulation for GERD ... implantable device designed to provide long-term reflux control by ... GERD affects nearly 65 million people in ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the ... of a moisturizer with the power of an anti-aging concentrate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular ... premier online modeling resource for fluorescence microscopists and optical system designers, enabling The ... 5 years spanning the globe, SearchLight has become a tremendously popular tool for ...
(Date:4/27/2017)... ... 27, 2017 , ... The Incentive Research Foundation is pleased ... Guide," a groundbreaking analysis of how behavioral economics can be applied to the ... IRR programs, the report highlights proven behavioral economics approaches and the powerful role ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The couple ... professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox and ...
Breaking Medicine News(10 mins):